<p>Terns Pharmaceuticals（纳斯达克代码：TERN - 获取免费报告）在周二向投资者发布的报告中，BMO 资本市场将其目标价格从 22.00 美元上调至 30.00 美元，Benzinga 报道。该公司目前对该股票的评级为 “跑赢大盘”。BMO 资本市场的目标价格表明，相较于该股票当前价格，存在 12.40% 的潜在上涨空间。</p>
<p>其他一些股票研究分析师最近也对该股票发布了报告。华尔街 Zen 在 10 月 25 日的报告中将 Terns Pharmaceuticals 的评级从 “卖出” 上调至 “持有”。JMP 证券在 10 月 23 日的研究报告中将 Terns Pharmaceuticals 的目标价格从 20.00 美元下调至 15.00 美元，并对该股票设定了 “市场跑赢大盘” 的评级。William Blair 在 11 月 3 日的研究报告中将 Terns Pharmaceuticals 的评级从 “市场表现” 上调至 “跑赢大盘”。HC Wainwright 在 11 月 4 日的研究报告中将 Terns Pharmaceuticals 的评级从 “中性” 上调至 “买入”，并设定了 20.00 美元的目标价格。最后，Oppenheimer 在 11 月 3 日的报告中重申了 “跑赢大盘” 的评级，并设定了 24.00 美元的目标价格。十位股票研究分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，平均目标价格为 26.63 美元。</p>
<p>获取 <strong>Terns Pharmaceuticals</strong> 的提醒：</p>
<p><strong>查看我们对 Terns Pharmaceuticals 的最新分析</strong></p>
<h2>Terns Pharmaceuticals 股票表现</h2>
<p>纳斯达克 TERN 在周二的交易中上涨了 1.13 美元，达到了 26.69 美元。该股票的交易量为 2,377,132 股，而其平均交易量为 1,525,396 股。Terns Pharmaceuticals 的 12 个月最低价为 1.87 美元，最高价为 27.41 美元。该公司的 50 日移动平均价格为 10.48 美元，200 日移动平均价格为 6.81 美元。该公司的市值为 24 亿美元，市盈率为-26.04，贝塔值为-0.02。</p>
<p>Terns Pharmaceuticals（纳斯达克代码：TERN - 获取免费报告）最后一次公布财报是在 11 月 10 日，报告显示该公司本季度每股收益为-0.27 美元，超出市场共识预期的-0.30 美元，超出幅度为 0.03 美元。整体来看，股票分析师预计 Terns Pharmaceuticals 在当前财政年度的每股收益为-1.19 美元。</p>
<h2>内部人士下注</h2>
<p>在其他新闻中，董事 Jill M. Quigley 在 11 月 4 日的交易中出售了 24,520 股公司的股票。该股票的平均售价为 18.00 美元，总交易额为 441,360.00 美元。该交易已在向证券交易委员会的备案中披露，相关信息可通过此链接获取。1.50% 的股票由公司内部人士持有。</p>
<h2>机构资金流入和流出</h2>
<p>一些对冲基金最近调整了对 TERN 的持股。Commodore Capital LP 在第三季度新建了约 4280.7 万美元的 Terns Pharmaceuticals 持仓。先锋集团在第三季度将其在 Terns Pharmaceuticals 的持股增加了 5.9%。先锋集团目前持有 4559917 股该公司的股票，价值 3424.5 万美元，此前在该期间内又购买了 253751 股。Candriam S.C.A.在第二季度将其在 Terns Pharmaceuticals 的持股增加了 9.9%。Candriam S.C.A.目前持有 2368235 股该公司的股票，价值 883.4 万美元，此前在该期间内又购买了 214266 股。Geode Capital Management LLC 在第二季度将其在 Terns Pharmaceuticals 的持股增加了 3.8%。Geode Capital Management LLC 目前持有 1633349 股该公司的股票，价值 609.4 万美元，此前在上个季度又购买了 59145 股。最后，Nuveen LLC 在第一季度购买了 Terns Pharmaceuticals 的新股份，价值约 388 万美元。机构投资者持有该公司 98.26% 的股票。</p>
<h2>关于 Terns Pharmaceuticals</h2>
<p>（获取免费报告）</p>
<p>Terns Pharmaceuticals, Inc 是一家临床阶段的生物制药公司，开发用于治疗肿瘤、代谢功能障碍相关性脂肪肝炎（MASH）和肥胖的小分子产品候选药物。该公司正在开发 TERN-701，这是一种别构 BCR-ABL 酪氨酸激酶抑制剂（TKI），目前正在进行慢性髓性白血病（CML）的 1 期临床试验，这是一种起源于骨髓的癌症。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票比 Terns Pharmaceuticals 更好</li>
<li>外汇是什么，如何运作？</li>
<li>为什么 20 秒的飞行测试可能为垂直市场解锁数十亿</li>
<li>什么使一只股票成为好的分红股票？</li>
<li>3 只适合不安市场的防御性股票</li>
<li>纳斯达克是什么？完整概述及历史</li>
<li>这 3 只股票正在利用回购来传达市场信心</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEVSTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEVSTg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Terns Pharmaceuticals 吗？</h2>
<p>在考虑 Terns Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Terns Pharmaceuticals 并不在名单上。</p>
<p>虽然 Terns Pharmaceuticals 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得买入。</p>
<p>在这里查看这五只股票</p>

TERN

<p>BMO 资本市场将 Terns Pharmaceuticals 的目标股价从 22.00 美元上调至 30.00 美元，维持 “跑赢大盘” 的评级。这表明当前股价有潜在的 12.40% 的上涨空间。其他分析师的评级各不相同，平均目标价为 26.63 美元。该股票最近的交易价格为 26.69 美元，市值为 24 亿美元</p>

<p>Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) had its target price increased by BMO Capital Markets from $22.00 to $30.00 in a note issued to investors on Tuesday,Benzinga reports. The firm presently has an &#34;outperform&#34; rating on the stock. BMO Capital Markets' target price indicates a potential upside of 12.40% from the stock's current price.</p>
<div class="lb-trans"><p>Terns Pharmaceuticals（纳斯达克代码：TERN - 获取免费报告）在周二向投资者发布的报告中，BMO 资本市场将其目标价格从 22.00 美元上调至 30.00 美元，Benzinga 报道。该公司目前对该股票的评级为 “跑赢大盘”。BMO 资本市场的目标价格表明，相较于该股票当前价格，存在 12.40% 的潜在上涨空间。</p>
</div><p>A number of other equities research analysts have also recently issued reports on the stock. Wall Street Zen raised shares of Terns Pharmaceuticals from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, October 25th. JMP Securities lowered their price target on Terns Pharmaceuticals from $20.00 to $15.00 and set a &#34;market outperform&#34; rating on the stock in a research report on Thursday, October 23rd. William Blair raised Terns Pharmaceuticals from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating in a research report on Monday, November 3rd. HC Wainwright upgraded Terns Pharmaceuticals from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and set a $20.00 price target on the stock in a research note on Tuesday, November 4th. Finally, Oppenheimer reaffirmed an &#34;outperform&#34; rating and set a $24.00 price target on shares of Terns Pharmaceuticals in a report on Monday, November 3rd. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $26.63.</p>
<div class="lb-trans"><p>其他一些股票研究分析师最近也对该股票发布了报告。华尔街 Zen 在 10 月 25 日的报告中将 Terns Pharmaceuticals 的评级从 “卖出” 上调至 “持有”。JMP 证券在 10 月 23 日的研究报告中将 Terns Pharmaceuticals 的目标价格从 20.00 美元下调至 15.00 美元，并对该股票设定了 “市场跑赢大盘” 的评级。William Blair 在 11 月 3 日的研究报告中将 Terns Pharmaceuticals 的评级从 “市场表现” 上调至 “跑赢大盘”。HC Wainwright 在 11 月 4 日的研究报告中将 Terns Pharmaceuticals 的评级从 “中性” 上调至 “买入”，并设定了 20.00 美元的目标价格。最后，Oppenheimer 在 11 月 3 日的报告中重申了 “跑赢大盘” 的评级，并设定了 24.00 美元的目标价格。十位股票研究分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，平均目标价格为 26.63 美元。</p>
</div><p>Get <strong>Terns Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Terns Pharmaceuticals</strong> 的提醒：</p>
</div><p><strong>View Our Latest Analysis on Terns Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Terns Pharmaceuticals 的最新分析</strong></p>
</div><h2>Terns Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Terns Pharmaceuticals 股票表现</h2>
</div><p>NASDAQ TERN traded up $1.13 during trading on Tuesday, hitting $26.69. The stock had a trading volume of 2,377,132 shares, compared to its average volume of 1,525,396. Terns Pharmaceuticals has a 12 month low of $1.87 and a 12 month high of $27.41. The company's 50-day moving average price is $10.48 and its two-hundred day moving average price is $6.81. The company has a market capitalization of $2.40 billion, a PE ratio of -26.04 and a beta of -0.02.</p>
<div class="lb-trans"><p>纳斯达克 TERN 在周二的交易中上涨了 1.13 美元，达到了 26.69 美元。该股票的交易量为 2,377,132 股，而其平均交易量为 1,525,396 股。Terns Pharmaceuticals 的 12 个月最低价为 1.87 美元，最高价为 27.41 美元。该公司的 50 日移动平均价格为 10.48 美元，200 日移动平均价格为 6.81 美元。该公司的市值为 24 亿美元，市盈率为-26.04，贝塔值为-0.02。</p>
</div><p>Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) last announced its earnings results on Monday, November 10th. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.03. As a group, equities analysts anticipate that Terns Pharmaceuticals will post -1.19 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Terns Pharmaceuticals（纳斯达克代码：TERN - 获取免费报告）最后一次公布财报是在 11 月 10 日，报告显示该公司本季度每股收益为-0.27 美元，超出市场共识预期的-0.30 美元，超出幅度为 0.03 美元。整体来看，股票分析师预计 Terns Pharmaceuticals 在当前财政年度的每股收益为-1.19 美元。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other news, Director Jill M. Quigley sold 24,520 shares of the company's stock in a transaction on Tuesday, November 4th. The stock was sold at an average price of $18.00, for a total transaction of $441,360.00. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. 1.50% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他新闻中，董事 Jill M. Quigley 在 11 月 4 日的交易中出售了 24,520 股公司的股票。该股票的平均售价为 18.00 美元，总交易额为 441,360.00 美元。该交易已在向证券交易委员会的备案中披露，相关信息可通过此链接获取。1.50% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of hedge funds have recently modified their holdings of TERN. Commodore Capital LP acquired a new position in Terns Pharmaceuticals in the third quarter valued at about $42,807,000. Vanguard Group Inc. increased its holdings in Terns Pharmaceuticals by 5.9% in the 3rd quarter. Vanguard Group Inc. now owns 4,559,917 shares of the company's stock valued at $34,245,000 after buying an additional 253,751 shares during the period. Candriam S.C.A. increased its holdings in Terns Pharmaceuticals by 9.9% in the 2nd quarter. Candriam S.C.A. now owns 2,368,235 shares of the company's stock valued at $8,834,000 after buying an additional 214,266 shares during the period. Geode Capital Management LLC raised its position in shares of Terns Pharmaceuticals by 3.8% in the 2nd quarter. Geode Capital Management LLC now owns 1,633,349 shares of the company's stock valued at $6,094,000 after buying an additional 59,145 shares in the last quarter. Finally, Nuveen LLC bought a new stake in shares of Terns Pharmaceuticals during the 1st quarter worth approximately $3,880,000. Institutional investors own 98.26% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金最近调整了对 TERN 的持股。Commodore Capital LP 在第三季度新建了约 4280.7 万美元的 Terns Pharmaceuticals 持仓。先锋集团在第三季度将其在 Terns Pharmaceuticals 的持股增加了 5.9%。先锋集团目前持有 4559917 股该公司的股票，价值 3424.5 万美元，此前在该期间内又购买了 253751 股。Candriam S.C.A.在第二季度将其在 Terns Pharmaceuticals 的持股增加了 9.9%。Candriam S.C.A.目前持有 2368235 股该公司的股票，价值 883.4 万美元，此前在该期间内又购买了 214266 股。Geode Capital Management LLC 在第二季度将其在 Terns Pharmaceuticals 的持股增加了 3.8%。Geode Capital Management LLC 目前持有 1633349 股该公司的股票，价值 609.4 万美元，此前在上个季度又购买了 59145 股。最后，Nuveen LLC 在第一季度购买了 Terns Pharmaceuticals 的新股份，价值约 388 万美元。机构投资者持有该公司 98.26% 的股票。</p>
</div><h2>About Terns Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Terns Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.</p>
<div class="lb-trans"><p>Terns Pharmaceuticals, Inc 是一家临床阶段的生物制药公司，开发用于治疗肿瘤、代谢功能障碍相关性脂肪肝炎（MASH）和肥胖的小分子产品候选药物。该公司正在开发 TERN-701，这是一种别构 BCR-ABL 酪氨酸激酶抑制剂（TKI），目前正在进行慢性髓性白血病（CML）的 1 期临床试验，这是一种起源于骨髓的癌症。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Terns Pharmaceuticals</li>
<li>What is Forex and How Does it Work?</li>
<li>Why a 20-Second Flight Test Could Unlock Billions for Vertical</li>
<li>What Makes a Stock a Good Dividend Stock?</li>
<li>3 Smart Defensive Stocks for an Uneasy Market</li>
<li>What is the Nasdaq? Complete Overview with History</li>
<li>These 3 Stocks Are Using Buybacks to Signal Market Confidence</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Terns Pharmaceuticals 更好</li>
<li>外汇是什么，如何运作？</li>
<li>为什么 20 秒的飞行测试可能为垂直市场解锁数十亿</li>
<li>什么使一只股票成为好的分红股票？</li>
<li>3 只适合不安市场的防御性股票</li>
<li>纳斯达克是什么？完整概述及历史</li>
<li>这 3 只股票正在利用回购来传达市场信心</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEVSTg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=TERN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Terns Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Terns Pharmaceuticals 吗？</h2>
</div><p>Before you consider Terns Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Terns Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Terns Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Terns Pharmaceuticals 并不在名单上。</p>
</div><p>While Terns Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Terns Pharmaceuticals 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得买入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

BMO 资本市场的分析师表示，Terns Pharmaceuticals（NASDAQ:TERN）的股价预计将会上涨